web analytics

Discuva Announces Extension of Ongoing Pharma Collaboration to Combat Life-Threatening Infections Caused by Multi-Drug Resistant Bacteria

Cambridge, UK, 21st February 2017 — Discuva, the antibiotics drug discovery and development company, today announced that its collaboration with Roche, originally initiated in February 2014, has been extended to February 2018 under a new contract amendment. The collaboration is focussed on the discovery and development of new antibiotics to treat life-threatening infections caused by multidrug resistant Gram-negative bacteria using Discuva’s proprietary SATIN technology platform. Financial terms of the extension have not been disclosed.

Discuva Awarded Innovate UK Grant to Develop New Antibiotics to Address Multidrug Resistance

Cambridge, UK, 25th January 2017 — Discuva, the antibiotics drug discovery and development company, today announced the receipt of a £1.5 million Biomedical Catalyst early-stage award from Innovate UK to develop novel antibiotics to tackle the issue of multidrug-resistance and life-threatening bacterial infections. The project, entitled “Exploitation of transport mechanisms for novel Gram-negative antibiotic drug discovery”, will leverage Discuva’s proprietary SATIN technology to explore new biological targets and deliver novel drug candidates that have a reduced likelihood of eliciting resistance compared to conventional antibiotics. According to the O’Neil Report on antimicrobial resistance, drug-resistant infections could kill 10 million people a year by 2050i .

Latest Tweets from @DiscuvaLtd

Discuva Ltd @DiscuvaLtd
RT @ppazaction: Untreatable #gonorrhea is here. The time to invest in #antibiotic research is NOW. https://t.co/XKNj1BszhI #SaveABX #superb
Discuva Ltd @DiscuvaLtd
RT @BSACandJAC: A new competition for 2018 will make up to £10 million available to UK organisations to work with Chinese partners #AMR htt…
Discuva Ltd @DiscuvaLtd
We all have the capacity to be experimental scientists. Let’s use it | Tom McLeish https://t.co/ADG4LBMYWp